Fresenius Medical Care AG & Co. KGaA

  • WKN: 578580
  • ISIN: DE0005785802
  • Land: Deutschland

Nachricht vom 30.12.2019 | 16:48

Fresenius Medical Care AG & Co. KGaA: Release of a capital market information

Fresenius Medical Care AG & Co. KGaA / Fresenius Medical Care AG & Co. KGaA / Announcement pursuant to Art. 5 para. 1 lit. b), para. 3 of Regulation (EU) No 596/2014 and Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052
30.12.2019 / 16:48
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Fresenius Medical Care AG & Co. KGaA: Disclosure of a capital market information

- Share buy-back - 28th Interim Report

In the period from December 23, 2019 until and including December 27, 2019, a total of 0 shares were repurchased within the framework of the share buy-back programme of Fresenius Medical Care AG & Co. KGaA ('Fresenius Medical Care') announced on June 14, 2019 pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052.

The purchase was carried out exclusively by a credit institution commissioned by Fresenius Medical Care via the XETRA trading platform on the Frankfurt Stock Exchange:

Day of repurchase Aggregated volume in number of shares Weighted average share price
in EUR
23.12.2019 - -
27.12.2019 - -
 

The total volume of shares repurchased within the framework of this share buy-back in the period from June 17, 2019 until and including December 27, 2019 therefore amounts to 5,107,678 shares.

Detailed information on the transactions pursuant to Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052 is available on Fresenius Medical Care's website at www.freseniusmedicalcare.com under section Investors.

Fresenius Medical Care AG & Co. KGaA
represented by Fresenius Medical Care Management AG
represented by its Management Board

Bad Homburg v.d.H., December 30, 2019



30.12.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

Signature AG

Original-Research: Signature AG (von Sphene Capital GmbH): Buy

28. September 2020